Lenograstim

Lenograstim is a recombinant granulocytes colony-stimulating factor which functions as an immunostimulator.

Indications

Redcution in the duration of neutropenia, Mobilisation of peripheral blood progenitor cells (PBPCs).

Dosage

150mg (19.2 MIU) per m2 per day as a 30-minutes intravenous infusion diluted in isotonic saline solution or as a subcetaneous injection.

Contra-Indications

Known hypersensitivity to lenograstim. It should not be administered concurrently with cytotoxic chemotherapy. It should not be administered to patients with myeloid malignancy other than de novo acute myeloid leukaemia, with de novo acute myeloid leukaemia aged below 55 years, and/or with de novo acute myeloid leukaemia with good cytogenetics.

Special Precautions

Severely impaired renal or hepatic function. People taking this medicine should have regular blood tests to check the levels of their blood components.

Side Effects

Disturbed hepatic function, hypotension, Thrombocytopenia, Anemia, Uricemia, Proteinuria, Musculoskeletal pain, Epistaxis.

Drug Interactions

Use of Lenograstim is not recommended from 24 hours before until 24 hours after chemotherapy ends.